vs

Side-by-side financial comparison of CPS TECHNOLOGIES CORP (CPSH) and SS Innovations International, Inc. (SSII). Click either name above to swap in a different company.

SS Innovations International, Inc. is the larger business by last-quarter revenue ($14.5M vs $8.2M, roughly 1.8× CPS TECHNOLOGIES CORP). CPS TECHNOLOGIES CORP runs the higher net margin — 0.2% vs -17.0%, a 17.2% gap on every dollar of revenue. On growth, SS Innovations International, Inc. posted the faster year-over-year revenue change (79.1% vs 38.3%). CPS TECHNOLOGIES CORP produced more free cash flow last quarter ($-487.0K vs $-3.2M). Over the past eight quarters, SS Innovations International, Inc.'s revenue compounded faster (99.9% CAGR vs 17.8%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

SS Innovations International, Inc. is a global medical technology enterprise specializing in the research, development and manufacturing of innovative surgical robotic systems. It provides high-precision, accessible robotic platforms for minimally invasive surgery, catering to healthcare facilities across multiple regions to boost surgical outcomes and cut procedural burdens.

CPSH vs SSII — Head-to-Head

Bigger by revenue
SSII
SSII
1.8× larger
SSII
$14.5M
$8.2M
CPSH
Growing faster (revenue YoY)
SSII
SSII
+40.7% gap
SSII
79.1%
38.3%
CPSH
Higher net margin
CPSH
CPSH
17.2% more per $
CPSH
0.2%
-17.0%
SSII
More free cash flow
CPSH
CPSH
$2.7M more FCF
CPSH
$-487.0K
$-3.2M
SSII
Faster 2-yr revenue CAGR
SSII
SSII
Annualised
SSII
99.9%
17.8%
CPSH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPSH
CPSH
SSII
SSII
Revenue
$8.2M
$14.5M
Net Profit
$12.6K
$-2.5M
Gross Margin
14.9%
43.9%
Operating Margin
-1.2%
-3.7%
Net Margin
0.2%
-17.0%
Revenue YoY
38.3%
79.1%
Net Profit YoY
101.3%
-28.5%
EPS (diluted)
$0.00
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSH
CPSH
SSII
SSII
Q4 25
$8.2M
$14.5M
Q3 25
$8.8M
$12.8M
Q2 25
$8.1M
$10.0M
Q1 25
$7.5M
$5.1M
Q4 24
$5.9M
$8.1M
Q3 24
$4.2M
$4.4M
Q2 24
$5.0M
$4.5M
Q1 24
$5.9M
$3.6M
Net Profit
CPSH
CPSH
SSII
SSII
Q4 25
$12.6K
$-2.5M
Q3 25
$208.0K
$-3.7M
Q2 25
$103.8K
$-256.7K
Q1 25
$96.0K
$-5.7M
Q4 24
$-995.2K
$-1.9M
Q3 24
$-1.0M
$-3.2M
Q2 24
$-954.3K
$-4.1M
Q1 24
$-143.2K
$-9.8M
Gross Margin
CPSH
CPSH
SSII
SSII
Q4 25
14.9%
43.9%
Q3 25
17.1%
48.1%
Q2 25
16.5%
59.1%
Q1 25
16.4%
21.2%
Q4 24
-4.6%
48.9%
Q3 24
-12.3%
52.8%
Q2 24
-4.6%
31.9%
Q1 24
15.3%
20.0%
Operating Margin
CPSH
CPSH
SSII
SSII
Q4 25
-1.2%
-3.7%
Q3 25
3.1%
-14.3%
Q2 25
1.7%
1.0%
Q1 25
1.7%
-115.6%
Q4 24
-22.2%
-22.7%
Q3 24
-35.0%
-73.1%
Q2 24
-26.1%
-90.9%
Q1 24
-4.4%
-270.3%
Net Margin
CPSH
CPSH
SSII
SSII
Q4 25
0.2%
-17.0%
Q3 25
2.4%
-29.0%
Q2 25
1.3%
-2.6%
Q1 25
1.3%
-111.0%
Q4 24
-16.8%
-23.7%
Q3 24
-24.6%
-74.0%
Q2 24
-19.0%
-91.8%
Q1 24
-2.4%
-270.5%
EPS (diluted)
CPSH
CPSH
SSII
SSII
Q4 25
$0.00
$-0.01
Q3 25
$0.01
$-0.02
Q2 25
$0.01
$0.00
Q1 25
$0.01
$-0.03
Q4 24
$-0.07
$-0.01
Q3 24
$-0.07
$-0.02
Q2 24
$-0.07
$-0.02
Q1 24
$-0.01
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSH
CPSH
SSII
SSII
Cash + ST InvestmentsLiquidity on hand
$13.2M
$3.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$24.6M
$38.2M
Total Assets
$29.5M
$74.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSH
CPSH
SSII
SSII
Q4 25
$13.2M
$3.2M
Q3 25
$4.3M
$5.7M
Q2 25
$3.4M
$11.4M
Q1 25
$3.0M
$15.9M
Q4 24
$4.3M
$466.5K
Q3 24
$5.7M
$220.4K
Q2 24
$7.1M
$608.2K
Q1 24
$8.7M
$948.1K
Total Debt
CPSH
CPSH
SSII
SSII
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
Q3 24
$20.1K
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
CPSH
CPSH
SSII
SSII
Q4 25
$24.6M
$38.2M
Q3 25
$15.1M
$39.6M
Q2 25
$14.9M
$42.0M
Q1 25
$14.7M
$40.6M
Q4 24
$14.5M
$13.5M
Q3 24
$15.4M
$13.7M
Q2 24
$16.4M
$14.8M
Q1 24
$17.3M
$16.7M
Total Assets
CPSH
CPSH
SSII
SSII
Q4 25
$29.5M
$74.2M
Q3 25
$20.4M
$69.6M
Q2 25
$19.4M
$70.0M
Q1 25
$19.2M
$63.5M
Q4 24
$18.9M
$42.4M
Q3 24
$19.2M
$39.0M
Q2 24
$20.1M
$35.7M
Q1 24
$21.2M
$35.2M
Debt / Equity
CPSH
CPSH
SSII
SSII
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSH
CPSH
SSII
SSII
Operating Cash FlowLast quarter
$243.6K
$-1.5M
Free Cash FlowOCF − Capex
$-487.0K
$-3.2M
FCF MarginFCF / Revenue
-5.9%
-22.3%
Capex IntensityCapex / Revenue
8.9%
11.8%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K
$-22.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSH
CPSH
SSII
SSII
Q4 25
$243.6K
$-1.5M
Q3 25
$1.1M
$-7.5M
Q2 25
$649.3K
$-3.5M
Q1 25
$-1.3M
$-6.1M
Q4 24
$-3.5M
$-3.3M
Q3 24
$-1.2M
$-2.5M
Q2 24
$-1.0M
$-1.0M
Q1 24
$128.9K
$-2.7M
Free Cash Flow
CPSH
CPSH
SSII
SSII
Q4 25
$-487.0K
$-3.2M
Q3 25
$876.8K
$-8.2M
Q2 25
$476.4K
$-3.8M
Q1 25
$-1.3M
$-7.0M
Q4 24
$-4.5M
$-3.4M
Q3 24
$-1.3M
$-4.2M
Q2 24
$-1.6M
$-3.1M
Q1 24
$-134.5K
$-2.8M
FCF Margin
CPSH
CPSH
SSII
SSII
Q4 25
-5.9%
-22.3%
Q3 25
10.0%
-64.1%
Q2 25
5.9%
-37.7%
Q1 25
-17.9%
-136.2%
Q4 24
-75.3%
-41.7%
Q3 24
-29.8%
-96.9%
Q2 24
-31.8%
-69.5%
Q1 24
-2.3%
-76.9%
Capex Intensity
CPSH
CPSH
SSII
SSII
Q4 25
8.9%
11.8%
Q3 25
2.0%
5.9%
Q2 25
2.1%
3.2%
Q1 25
1.2%
17.0%
Q4 24
16.8%
1.5%
Q3 24
1.9%
38.8%
Q2 24
11.0%
46.8%
Q1 24
4.5%
3.5%
Cash Conversion
CPSH
CPSH
SSII
SSII
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CPSH
CPSH

Segment breakdown not available.

SSII
SSII

System Sales$13.4M92%
Other$1.2M8%

Related Comparisons